Sep 18, 2013, 02.39 PM | Source: CNBC-TV18
Manoj Murlidharan Vayalar of IIFL recommends selling Sun Pharmaceutical Industries with a target of Rs 520 and a stoploss at Rs 555.
Manoj Murlidharan (more)
Head- Derivatives, Religare Securities | Capital Expertise: F&O
At 14:12 hrs Sun Pharmaceutical Industries was quoting at Rs 544.55, up Rs 0.20, or 0.04 percent. It has touched an intraday high of Rs 550 and an intraday low of Rs 535.55.
The share touched its 52-week high Rs 583 and 52-week low Rs 344.73 on 16 September, 2013 and 15 November, 2012, respectively. Currently, it is trading 6.6 percent below its 52-week high and 57.96 percent above its 52-week low. Market capitalisation stands at Rs 112,785.23 crore.
Disclosure: We have discussed this with our clients but no personal holdings.
Sun Pharma launched Gleevec generic on February 1,
"One of the company's US subsidiaries, Sun Pharmac
Ashwani Gujral of ashwanigujral.com recommends buy
Daiichi Sankyo, Daiichi Sankyo (Thailand) Ltd, Sun
Sun Pharmaceutical Industries' board meeting will
On CNBC-TV18's show Super Six, market gurus Vishal
Union Bank of India | ONGC | BHEL | Akzo Noble | F